<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149737">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01997788</url>
  </required_header>
  <id_info>
    <org_study_id>ITMPKidney</org_study_id>
    <nct_id>NCT01997788</nct_id>
  </id_info>
  <brief_title>The Intrathecal Morphine for Nephrectomy</brief_title>
  <acronym>EMPON</acronym>
  <official_title>The Efficacy of Intrathecal Morphine in Patients Undergoing Open Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and the safety of the intrathecal morphine injection in the open
      nephrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The open nephrectomy is the treatment of choice for live donor kidney transplantation and
      renal cell carcinoma. The incision for the nephrectomy causes severe postoperative pain. A
      single dose of intrathecal morphine(ITM) has been used for the postoperative pain of
      prostatectomy, transurethral resection of the prostate and hepatectomy. The effect of ITM
      for open nephrectomy has not been studied. Therefore, this prospective, randomized study
      will evaluate the efficacy and safety of a single 50 mcg dose of ITM added to intravenous
      patient controlled analgesia(IV-PCA), comparing to IV-PCA alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The evaluation of pain at 24 hours after surgery</measure>
    <time_frame>at postoperatively 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The doctor blinded to the investigation will visit patients. The pain will be assessed at rest and at coughing using visual analogue scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The consumption of analgesics</measure>
    <time_frame>at postoperatively 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total amount of opioids (IV morphine) used for 24 hours after surgery will be recorded and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The consumption of intraoperative opioids</measure>
    <time_frame>From the induction of anesthesia till the emergence of anesthesia, an expected average of 4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total amount of intraoperative opioids (IV remifentanil) will be recorded and compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The side effects of opioids after surgery</measure>
    <time_frame>During 72 hours after the end of surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any side effects of opioids including nausea, vomiting, dizziness, sedation, headache,  pruritus and respiratory depression will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>The ITM group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The IV-PCA group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The intrathecal morphine injection</intervention_name>
    <description>A single injection of morphine intrathecally</description>
    <arm_group_label>The ITM group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The intravenous patient-controlled analgesia</intervention_name>
    <description>The intravenous injection of morphine using the patient-controlled analgesia machine</description>
    <arm_group_label>The ITM group</arm_group_label>
    <arm_group_label>The IV-PCA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Demerol on demand</intervention_name>
    <description>Demerol 25 mg intravenously when pain scores more than 5.</description>
    <arm_group_label>The ITM group</arm_group_label>
    <arm_group_label>The IV-PCA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for the open nephrectomy

        Exclusion Criteria:

          -  Patients with renal insufficiency

          -  Patients with coagulopathy

          -  History of any neurologic disorder

          -  History of recent infection in 2 weeks

          -  History of drug abuse

          -  Patients who cannot understand the usage of th intravenous patient-controlled
             analgesia

          -  Patients using opioids due to the chronic pain
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deok-Man Hong, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University of Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Chang Kim, MD</last_name>
    <phone>89-1028862876</phone>
    <email>onidori1979@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University of Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Chang Kim, MD</last_name>
      <phone>82-1028862876</phone>
      <email>onidori1979@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyun-Chang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 24, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Deok Man Hong</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Injection, Spinal</keyword>
  <keyword>Morphine</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Patient-Controlled</keyword>
  <keyword>Pain</keyword>
  <keyword>Postoperative</keyword>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Nephrectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
